Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 19Small Cell Lung Carcinoma 10Lung Neoplasms 10Squamous Cell Carcinoma of Head and Neck 8Cholangiocarcinoma 7Pancreatic Neoplasms 6Ovarian Neoplasms 6Oropharyngeal Neoplasms 6Fallopian Tube Neoplasms 6Urinary Bladder Neoplasms 5Breast Neoplasms 5Uterine Cervical Neoplasms 4Gallbladder Neoplasms 4Brain Neoplasms 4Adenocarcinoma of Lung 4Stomach Neoplasms 3Sarcoma 3Mouth Neoplasms 3Mesothelioma, Malignant 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Carcinoma 3Urethral Neoplasms 2Triple Negative Breast Neoplasms 2Testicular Neoplasms 2Seminoma 2Salivary Gland Neoplasms 2Recurrence 2Prostatic Neoplasms 2Peritoneal Neoplasms 2

Interventions

pembrolizumab 2Radiotherapy 2Etoposide 2Carboplatin 2sintilimab 1irinotecan sucrosofate 1durvalumab 1atezolizumab 1apatinib 1anlotinib 1amrubicin 1Platinum 1Paclitaxel 1Observation 1NPI 2358 1Immunotherapy 1Immune Checkpoint Inhibitors 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Small Cell Lung Cancer Extensive Stage × Platinum × Clear all
NCT05745350 2025-02-11

First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Recruiting
45 enrolled
Thoracic

Small Cell Lung Cancer Extensive Stage

Data powered by HemOnc (CC BY 4.0) Colophon âš¡